Business Context and Reporting Period
Surrozen, Inc. filed a Form 8-K reporting that its wholly owned subsidiary, Surrozen Operating, Inc., entered into a Collaboration and License Agreement with Boehringer Ingelheim International GmbH on September 30, 2022. The agreement covers research, development, and commercialization of Fzd4 bispecific antibodies designed using Surrozen’s SWAP technology, including SZN-413, a development candidate for retinal vascular-associated diseases.
The filing was signed on October 6, 2022. It does not include quarterly financial statements or results for the period ended September 30, 2022.
Financial and Commercial Terms
- Surrozen will receive a $12.5 million upfront payment.
- Surrozen is eligible for up to $586.5 million in development, regulatory, and commercial milestone payments.
- Surrozen is eligible for mid-single-digit to low-double-digit royalties on potential net commercial sales of licensed products.
- Royalty payments may be reduced for patent expiration, generic competition, and certain third-party intellectual-property license payments.
- Boehringer Ingelheim will fund and assume responsibility for further research, preclinical and clinical development, manufacturing, regulatory approvals, and commercialization after the collaborative research period.
Material Changes and Agreement Structure
- The parties will conduct collaborative research focused on SZN-413 for one year, with Boehringer Ingelheim holding an option to extend the period by up to six months.
- Following the research period, Boehringer Ingelheim may select one lead and two backup Fzd4 bispecific antibodies.
- Boehringer Ingelheim will receive an exclusive, royalty-bearing, worldwide, sublicensable license to develop, manufacture, and commercialize the selected antibodies and derivatives for all uses.
- For five years after the effective date, Surrozen may not preclinically or clinically develop or commercialize Fzd4 bispecific antibodies for eye diseases. Boehringer Ingelheim may not clinically develop or commercialize licensed products outside eye diseases during that period.
Guidance, Outlook, Risks, and Unusual Items
The agreement creates potential near-term cash proceeds and significant contingent milestone and royalty opportunities, but the milestone payments and commercial royalties depend on successful research, development, regulatory approval, and commercialization. The filing provides no earnings, cash-flow, liquidity, debt, margin, or financial guidance data.
- Boehringer Ingelheim may terminate the agreement for any reason after a specified notice period.
- Either party may terminate for the other party’s bankruptcy or material uncured breach.
- The agreement continues by product and country until expiration of the applicable royalty term unless terminated earlier.
- The filing states that the description is qualified by the complete agreement, which was expected to be filed as an exhibit to Surrozen’s Form 10-Q for the quarter ended September 30, 2022.
Key Facts for Investors to Verify
- Receipt and accounting treatment of the $12.5 million upfront payment.
- Recognition, timing, and probability of any milestone payments.
- The full milestone schedule, royalty rates, royalty reductions, and third-party intellectual-property obligations in the definitive agreement.
- Whether Boehringer Ingelheim extends the collaborative research period and which antibodies it selects.
- Any subsequent termination, development, regulatory, or commercialization updates.
- Surrozen’s separate financial position, cash runway, operating expenses, debt, and liquidity, which are not provided in this 8-K.